List of Excipients in Branded Drug SALONPAS ARTHRITIS PAIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hisamitsu Pharmaceutical Co Inc	SALONPAS ARTHRITIS PAIN	menthol, methyl salicylate	46581-680	ALUMINUM SILICATE	2030-01-03
Hisamitsu Pharmaceutical Co Inc	SALONPAS ARTHRITIS PAIN	menthol, methyl salicylate	46581-680	MINERAL OIL	2030-01-03
Hisamitsu Pharmaceutical Co Inc	SALONPAS ARTHRITIS PAIN	menthol, methyl salicylate	46581-685	ALUMINUM SILICATE	2030-01-03
Hisamitsu Pharmaceutical Co Inc	SALONPAS ARTHRITIS PAIN	menthol, methyl salicylate	46581-685	MINERAL OIL	2030-01-03

SALONPAS ARTHRITIS PAIN Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Salonpas Arthritis Pain is a consumer topical diclofenac sodium product marketed for temporary relief of arthritis pain. Its commercial opportunity is driven less by active-ingredient exclusivity and more by excipient-enabled differentiation: skin feel, drying time, odor, tube usability, dose consistency, irritation control, and channel-specific packaging. The strongest development path is a low-residue, fast-drying, skin-tolerant gel platform that supports premium OTC positioning without creating avoidable regulatory or manufacturing complexity.

What is SALONPAS ARTHRITIS PAIN and what active ingredient does it contain?

Salonpas Arthritis Pain is a topical nonsteroidal anti-inflammatory drug product containing diclofenac sodium at 1% strength. The product is intended for temporary relief of arthritis pain in accessible joints, including the hands, wrists, elbows, feet, ankles and knees, consistent with FDA labeling for topical diclofenac sodium gel products (FDA, 2020; DailyMed, 2024).

Attribute	Product profile
Brand	Salonpas Arthritis Pain
Manufacturer/marketer	Hisamitsu-related Salonpas commercial platform
Active ingredient	Diclofenac sodium
Strength	1% topical gel
Drug class	Topical NSAID
Primary use	Temporary relief of arthritis pain
Dosage form	Topical gel
Primary route	Cutaneous
Regulatory category	OTC topical arthritis-pain product
Main competitors	Voltaren Arthritis Pain, store-brand diclofenac sodium gel, topical analgesic products

Diclofenac sodium is the principal therapeutic driver. The excipient system determines whether consumers perceive the product as effective, convenient and tolerable.

What excipients are important in diclofenac sodium topical gel?

The key excipient functions are solubilization, rheology control, skin delivery, preservation, pH adjustment, sensory performance and package compatibility.

A conventional diclofenac sodium gel platform can include:

Excipient function	Candidate excipient classes	Commercial purpose
Vehicle	Purified water, alcohols, glycols	Dissolves or disperses drug and controls evaporation
Humectancy	Propylene glycol, glycerin, polyethylene glycol	Limits drying and improves skin feel
Thickening	Carbomer, acrylate polymers, cellulose derivatives	Controls viscosity, spreadability and dose retention
Neutralization	Sodium hydroxide, tromethamine, ammonia or amines	Builds gel structure and adjusts pH
Solubilization	Glycols, surfactants, cosolvents	Maintains drug uniformity
Emulsion support	Nonionic surfactants, fatty esters	Stabilizes complex vehicles
Preservation	Phenoxyethanol, parabens, organic acids or approved alternatives	Controls microbial growth
Skin conditioning	Emollients and ester oils	Reduces tack and improves application
Chelation	Disodium EDTA	Supports preservative performance and stability
Packaging protection	Low-permeability tube or pump components	Limits solvent loss and drug migration

The formulation target is not maximum solvent content. Excess alcohol can improve drying but increase stinging, dryness and flammability concerns. Excess glycols can increase tackiness and prolong wetness. Excess polymer can reduce spreadability and leave visible residue.

How should an excipient strategy be designed for Salonpas Arthritis Pain?

The preferred strategy is a balanced hydroalcoholic or aqueous-glycol gel with moderate polymer loading and controlled neutralization.

1. Optimize skin feel before maximizing drug loading

Diclofenac sodium is already available at a commercially established 1% concentration. A reformulation should focus on:

• Rapid spreading over a joint surface
• Limited pilling after drying
• Low tack after one to two minutes
• Minimal whitening or visible film
• Low odor
• Reduced transfer to clothing
• Consistent dosing from the first to the final application

A carbomer-based system is commercially practical because it offers strong viscosity control at relatively low use levels. Acrylate crosspolymers can provide improved clarity and a less stringy texture, but compatibility with electrolytes, pH and preservative systems must be confirmed.

2. Control pH and ionic strength

Diclofenac sodium is sensitive to the formulation environment. Polymer viscosity, drug solubility, preservative performance and skin tolerability can shift with pH and ionic strength.

A development target should balance:

• Drug solubility
• Polymer hydration
• Chemical stability
• Skin compatibility
• Container closure stability

Neutralization should be tightly controlled. Excess base can increase irritation risk and destabilize the gel structure. A buffered system may improve batch consistency, but unnecessary buffer salts can reduce viscosity and complicate stability.

3. Reduce sensory disadvantages of alcohol

Alcohol can support quick drying and antimicrobial performance, but its level should be optimized against skin tolerance. A lower-alcohol system using volatile co-solvents, controlled polymer architecture or optimized water-glycol ratios may create a better experience for older arthritis consumers, who often have dry or fragile skin.

An alcohol-reduced formulation could support claims such as:

• Non-greasy feel
• Fast absorption or fast drying, if substantiated
• Low residue
• Comfortable daily use

Claims must remain consistent with FDA OTC labeling and supporting consumer-use data.

4. Use excipients with established topical precedent

The lowest regulatory-risk strategy uses excipients with broad topical pharmaceutical or OTC precedent. Novel delivery enhancers can improve permeation but may create new irritation, sensitization, toxicology and regulatory burdens.

High-risk choices include:

• Aggressive penetration enhancers
• Fragrance systems
• Essential oils
• High surfactant loads
• Novel nanocarriers
• Strong counterirritants
• Preservatives with higher sensitization concerns

Fragrance is especially difficult to justify in an arthritis product used by older adults and applied repeatedly. A fragrance-free positioning is commercially stronger.

What formulations are protected by Salonpas Arthritis Pain or competing products?

The commercial formulation opportunity is primarily an improvement strategy rather than a basic diclofenac composition strategy. Diclofenac sodium topical gel has a mature public prior-art base, and broad claims covering the active ingredient in a conventional gel are likely to face substantial validity and freedom-to-operate pressure.

Potentially protectable subject matter includes:

1. Specific excipient ratios that produce a defined viscosity and drying profile.
2. Low-residue gel systems with controlled diclofenac release.
3. Alcohol-reduced compositions with equivalent skin delivery.
4. Preservative-free or self-preserving systems.
5. Packaging that reduces solvent loss and maintains dose uniformity.
6. Unit-dose or metered-dose delivery systems.
7. Stabilized formulations with improved impurity profiles.
8. Formulations designed for use on sensitive or aged skin.
9. Manufacturing processes that improve content uniformity.
10. Combination products that integrate an applicator, dosing aid or compliant closure.

A formulation patent should not rely only on ingredient inclusion. Stronger claims would link composition to measurable performance, such as viscosity range, drying time, diclofenac flux, residual solvent, impurity control or stability after repeated opening.

What is the Orange Book status of SALONPAS ARTHRITIS PAIN?

Salonpas Arthritis Pain is marketed as an OTC topical product rather than as a conventional prescription product protected by an extensive Orange Book patent listing. The principal commercial barriers are therefore brand recognition, FDA compliance, product quality, retail placement, consumer loyalty and manufacturing scale.

The relevant regulatory issues include:

• Compliance with applicable OTC drug requirements
• Accurate active-ingredient labeling
• Adequate directions and warnings
• cGMP compliance
• Stability and microbial-control data
• Container-closure qualification
• Postmarket adverse-event monitoring
• Advertising substantiation

OTC status reduces dependence on prescription-style patent exclusivity. It also makes formulation differentiation and retail execution more important.

When does SALONPAS ARTHRITIS PAIN lose exclusivity?

Salonpas Arthritis Pain does not have a conventional small-molecule prescription exclusivity date that determines generic entry. Generic or private-label competition can enter through legally compliant OTC pathways, subject to applicable FDA requirements and manufacturing controls.

The competitive lifecycle is therefore better described as follows:

Lifecycle factor	Commercial effect
Active ingredient maturity	Limits broad composition-of-matter protection
OTC pathway	Lowers dependence on Orange Book litigation
Brand recognition	Supports price premium and shelf placement
Formulation experience	Can create practical but often nonexclusive advantages
Packaging and applicator	Can delay direct substitution
Retail contracts	Can influence channel access
Consumer reviews	Can affect repeat purchase
Manufacturing scale	Influences cost and retailer margins

The most credible launch threat is a store-brand diclofenac sodium gel with similar strength and conventional excipients. A differentiated product needs a clear consumer benefit beyond the 1% diclofenac label.

Which companies are challenging the SALONPAS commercial position?

The competitive field includes branded, private-label and specialty topical-analgesic manufacturers.

Competitor category	Examples	Principal competitive lever
Branded diclofenac gel	Voltaren Arthritis Pain	Physician awareness, pharmacy presence, brand trust
Retail private labels	Store-brand diclofenac sodium gel	Lower price
Topical analgesics	Lidocaine, menthol, capsaicin products	Alternative mechanism or sensory effect
Patch products	Salonpas and competing patches	Convenience and controlled application
Compounded products	Local pharmacies and specialty providers	Customized dosage forms
Digital-health brands	Online topical pain products	Direct-to-consumer acquisition

Voltaren is the closest branded comparator because it established broad consumer awareness for OTC topical diclofenac. Private-label products create the greatest price pressure. Salonpas can defend share through superior application experience, package convenience and cross-selling across its topical pain portfolio.

How does SALONPAS compare with Voltaren Arthritis Pain?

Factor	Salonpas Arthritis Pain	Voltaren Arthritis Pain
Active ingredient	Diclofenac sodium	Diclofenac sodium
Strength	1%	1%
Core indication	Arthritis pain	Arthritis pain
Main differentiation opportunity	Sensory profile, packaging, brand ecosystem	Brand awareness and pharmacy presence
Price pressure	High from private labels	High from private labels
Patent leverage	Limited at active-ingredient level	Limited at active-ingredient level
Commercial defense	Retail execution and product experience	Established consumer and healthcare recognition

The products are therapeutically close at the label level. Excipient differentiation can matter because consumers repeatedly handle the product, apply it to painful joints and make judgments based on residue, odor, drying time and ease of use.

What commercial opportunities exist for an improved Salonpas formulation?

Premium low-residue gel

A fast-drying, non-greasy gel could support a moderate premium over store-brand products. The opportunity is strongest in pharmacy, mass retail and e-commerce channels where consumers compare reviews and product descriptions.

Sensitive-skin formulation

A fragrance-free, reduced-alcohol formulation could target older consumers and users with dry skin. The product should avoid overstated dermatological claims unless supported by controlled testing.

Metered-dose pump

A metered pump can improve dose consistency, reduce tube contamination and provide a more premium user experience. It also creates packaging differentiation that is harder for low-cost competitors to copy without changing their production lines.

Travel and adherence formats

Single-use sachets, small tubes and compact pumps could support travel, workplace use and medication adherence. These formats increase packaging cost but may improve trial conversion.

Arthritis-care system

Salonpas could combine gel, patch and accessory products in an arthritis-care platform. Bundles could include a topical gel for repeated use and a patch for longer wear. This strategy increases basket size without changing the diclofenac formulation.

International expansion

Diclofenac topical products have broad international demand, but regulatory requirements, allowed excipients, labeling rules and market authorization pathways vary by jurisdiction. A platform based on well-established excipients can reduce regional reformulation requirements.

What manufacturing and intellectual-property barriers exist?

The primary manufacturing barriers are process control rather than scarce raw materials. Critical controls include:

• Mixing order and shear rate
• Polymer hydration time
• Neutralization endpoint
• Air incorporation
• Drug uniformity
• Viscosity drift
• Alcohol or solvent loss
• Microbial control
• Tube filling accuracy
• Container compatibility

A scalable process should minimize air entrapment and control the time between neutralization and filling. Carbomer gels can show batch-to-batch viscosity variation when hydration, ionic strength or neutralization is poorly controlled.

Freedom-to-operate review should cover:

• Gel composition claims
• Diclofenac topical delivery patents
• Metered-dose packaging
• Applicator and closure designs
• Manufacturing methods
• Stability and impurity-control claims
• Formulation patents owned by branded competitors

No Paragraph IV challenge is central to the OTC Salonpas product in the way it would be for a prescription NDA. Competitors would more likely enter through their own compliant OTC products or private-label arrangements.

How strong is the patent estate for SALONPAS ARTHRITIS PAIN?

The likely patent position is stronger around execution-specific improvements than around diclofenac itself. A durable estate would need several claim layers:

Claim layer	Expected strength
Diclofenac sodium as an analgesic	Weak due to established prior art
Diclofenac sodium 1% gel	Weak to moderate, depending on claim scope
Specific excipient ratios	Moderate if tied to performance
Low-residue or fast-drying formulation	Moderate if supported by comparative data
Packaging and dosing system	Moderate to strong for narrow designs
Manufacturing controls	Moderate if process-critical and non-obvious
Brand and trade dress	Commercially important but separate from formulation patents

A practical filing program would use composition, process, packaging and performance claims. Trade-secret protection should cover mixing parameters, order of addition, in-process controls and stability-improving manufacturing details that are difficult to reverse engineer.

What revenue exposure exists if private-label competition expands?

Private-label entry can compress price and retailer margins across the topical diclofenac category. Exposure is highest for undifferentiated tube products with similar active strength and consumer instructions.

Revenue defense depends on:

1. Maintaining pharmacy and mass-retail distribution.
2. Preserving brand visibility.
3. Offering a clear sensory or usability advantage.
4. Building e-commerce review density.
5. Using pack sizes and bundles to manage price comparison.
6. Controlling manufacturing cost.
7. Protecting high-value packaging and formulation features.

The best commercial design is not necessarily the most technically complex formulation. A modestly improved gel with strong consumer acceptance can outperform a sophisticated delivery system that adds cost without a visible benefit.

What generic launch scenarios exist?

Low-cost conventional gel

This is the most probable competitive scenario. The product matches diclofenac strength and uses standard gel excipients. It competes primarily on price.

Premium sensory-equivalent gel

A competitor may reproduce a fast-drying, low-residue profile without copying protected claims. This would reduce the value of sensory differentiation unless the brand has strong loyalty.

Private-label pump

Retailers may prefer a pump if it reduces leakage and improves shelf presentation. Pump packaging can shift competition from formulation to package economics.

Multi-product pain portfolio

A competitor may bundle diclofenac gel with lidocaine, menthol or patch products. This can increase customer acquisition and reduce Salonpas’ portfolio advantage.

Cross-border formulation transfer

A manufacturer may adapt an existing diclofenac gel from another jurisdiction. Excipients, labeling and regulatory status would require local review, but the technical development timeline could be shorter than for a new platform.

Key Takeaways

• Salonpas Arthritis Pain is a 1% diclofenac sodium topical gel marketed for arthritis pain.
• The active ingredient offers limited differentiation because topical diclofenac is mature and widely available.
• The strongest excipient opportunity is a fragrance-free, low-residue, fast-drying gel with controlled irritation and strong package compatibility.
• Carbomer or acrylate-polymer systems remain commercially practical, but viscosity, neutralization and ionic strength require tight process control.
• The product does not rely on a conventional prescription Orange Book exclusivity timeline.
• Private-label diclofenac gel is the principal generic threat.
• The most defensible intellectual property would cover specific composition-performance relationships, manufacturing controls and metered-dose packaging.
• Commercial upside is greatest in premium OTC, pharmacy, e-commerce, sensitive-skin and adherence-oriented formats.
• A formulation improvement should produce a visible consumer benefit without imposing excessive manufacturing or regulatory complexity.

FAQs

Can Salonpas Arthritis Pain be reformulated without changing the diclofenac strength?

Yes. The excipient system, polymer, solvent balance, preservative approach, package and dosing mechanism can change while maintaining 1% diclofenac sodium, subject to regulatory and quality requirements.

Is a fragrance-free Salonpas arthritis gel commercially attractive?

Yes. Fragrance-free positioning can appeal to older consumers, frequent users and people who avoid scented topical products. The formulation must still achieve acceptable odor from the active ingredient and solvent system.

Which excipient creates the biggest sensory difference?

The solvent and polymer combination usually has the greatest effect on drying time, tack, residue and spreadability. Humectants and emollients then modify after-feel and skin comfort.

Would a pump package strengthen market exclusivity?

A pump would not create broad drug exclusivity, but it could support narrow packaging patents, trade-dress protection, dosing differentiation and retailer segmentation.

Is a diclofenac gel patent likely to block an OTC competitor?

A broad patent covering diclofenac sodium in a conventional topical gel would face substantial prior-art pressure. A narrowly drafted patent covering a specific excipient ratio, performance profile, manufacturing step or delivery package may create a more meaningful barrier.

References

1. DailyMed. (2024). Diclofenac sodium topical gel, 1%: Drug labeling information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter topical nonsteroidal anti-inflammatory drug for arthritis pain. FDA.

3. U.S. Food and Drug Administration. (2024). Over-the-counter drug products and nonprescription drug labeling requirements. FDA.

4. United States Pharmacopeia. (2024). General chapters for semisolid dosage forms, topical products and pharmaceutical quality. United States Pharmacopeial Convention.